Target Information

Target General Infomation
Target ID
T94033
Former ID
TTDS00202
Target Name
Coagulation factor IIa
Gene Name
F2
Synonyms
Coagulation factor II; Prothrombin; F2
Target Type
Successful
Disease Atopic dermatitis [ICD9: 691.8, 692.9; ICD10: L00-L99]
Angina pectoris [ICD9: 413; ICD10: I20]
Bleeding [ICD9: 444, 453; ICD10: I74, I80-I82]
Blood coagulation disorders [ICD10: D65-D68]
Blood forming organ disorders [ICD10: D75.9]
Coagulation [ICD10: I80-I82]
Cardiovascular disorder [ICD10: I00-I99]
Cancer [ICD9: 140-229; ICD10: C00-C96]
Heart arrhythmia [ICD10: I47-I49]
Myocardial infarction [ICD9: 410; ICD10: I21, I22]
Nonvalvular atrial fibrillation; Thrombosis [ICD9: 427.31, 437.6, 453, 671.5, 671.9; ICD10: I48, I80-I82]
Neurological disease [ICD9: 338, 338.2, 410, 782.3,780; ICD10: I21, I22, R52, R52.1-R52.2, R60.9, G89]
Stroke in atrial fibrillation [ICD9: 427.31, 434.91; ICD10: I48, I61-I63]
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48]
Thrombosis [ICD9: 437.6, 453, 671.5, 671.9; ICD10: I80-I82]
Thromboembolism [ICD9: 437.6, 453, 671.5, 671.9; ICD10: I80-I82]
Thrombocytopenia [ICD9: 287.3, 287.4, 287.5; ICD10: D69.6, P61.0]
Venous thrombosis [ICD9: 437.6, 453, 671.5, 671.9; ICD10: I80-I82]
Unspecified [ICD code not available]
Function
Thrombin, which cleaves bonds after arg and lys, converts fibrinogen to fibrin and activates factors v, vii, viii, xiii, and, in complex with thrombomodulin, protein c.
BioChemical Class
Peptidase
Target Validation
T94033
UniProt ID
P00734
EC Number
EC 3.4.21.5
Sequence
MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC
VEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV
NITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE
CSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA
QAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG
DGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI
DGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN
DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP
VCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST
RIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY
GFYTHVFRLKKWIQKVIDQFGE
Drugs and Mode of Action
Drug(s) Anisindione Drug Info Approved Coagulation [1], [2]
Bivalirudin Drug Info Approved Thrombocytopenia [3], [4]
Dabigatran Drug Info Approved Stroke in atrial fibrillation [5], [6]
Lepirudin Drug Info Approved Thrombocytopenia [3], [7]
Hirudin Drug Info Phase 4 Discovery agent [8]
MELAGATRAN Drug Info Phase 3 Discovery agent [9], [10]
SR-123781A Drug Info Phase 2/3 Venous thrombosis [11]
EFEGATRAN SULFATE HYDRATE Drug Info Phase 2 Myocardial infarction [12]
EP-217609 Drug Info Phase 2 Thrombosis [13]
LB-30870 Drug Info Phase 2 Myocardial infarction [14]
NU-172 Drug Info Phase 2 Thrombosis [15]
Odiparcil Drug Info Phase 2 Cardiovascular disorder [16]
Pegmusirudin Drug Info Phase 2 Angina pectoris [17]
Recombinant RGD-hirudin Drug Info Phase 2 Thrombosis [18]
AZD-8165 Drug Info Phase 1 Thrombosis [19], [20]
DP-4088 Drug Info Phase 1 Blood coagulation disorders [21]
EP-42675 Drug Info Phase 1 Thrombosis [22]
RWJ-671818 Drug Info Phase 1 Thrombosis [23]
Solulin Drug Info Phase 1 Thrombosis [24]
SSR-128428 Drug Info Phase 1 Thromboembolism [25]
H376/95 Drug Info Withdrawn from market Discovery agent [26]
Ximelagatran Drug Info Withdrawn from market Coagulation [3], [27]
AZD0837 Drug Info Discontinued in Phase 2 Nonvalvular atrial fibrillation; Thrombosis [28], [29]
Dermolastin Drug Info Discontinued in Phase 2 Atopic dermatitis [30]
INOGATRAN Drug Info Discontinued in Phase 2 Myocardial infarction [31]
Napsagatran Drug Info Discontinued in Phase 2 Myocardial infarction [32]
SSR-182289 Drug Info Discontinued in Phase 2 Myocardial infarction [33]
Vasoflux Drug Info Discontinued in Phase 2 Myocardial infarction [34]
ARC-183 Drug Info Discontinued in Phase 1 Blood forming organ disorders [35]
BCX-1470 Drug Info Discontinued in Phase 1 Bleeding [36]
CJC-1004 Drug Info Discontinued in Phase 1 Thrombosis [37]
CVS-1123 Drug Info Discontinued in Phase 1 Myocardial infarction [38]
GW-473178 Drug Info Discontinued in Phase 1 Heart arrhythmia [39]
Licostinel Drug Info Discontinued in Phase 1 Neurological disease [40]
MPC-0920 Drug Info Discontinued in Phase 1 Thrombosis [41]
S-18326 Drug Info Discontinued in Phase 1 Myocardial infarction [42]
UK-156406 Drug Info Discontinued in Phase 1 Myocardial infarction [43]
BCH-2763 Drug Info Terminated Thrombosis [44]
BMS-189664 Drug Info Terminated Myocardial infarction [45]
CVS-995 Drug Info Terminated Myocardial infarction [46]
DuP 714 Drug Info Terminated Thromboembolism [47]
Efegatran Drug Info Terminated Discovery agent [48]
GS-522 Drug Info Terminated Thromboembolism [49]
Hementin Drug Info Terminated Thromboembolism [50]
L-373890 Drug Info Terminated Thrombosis [51]
L-374,087 Drug Info Terminated Thrombosis [52]
LB30057 Drug Info Terminated Discovery agent [53]
Org-34092 Drug Info Terminated Thromboembolism [54]
PPACK Drug Info Terminated Discovery agent [55]
SR-80027A Drug Info Terminated Thromboembolism [56]
Inhibitor (3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone Drug Info [57]
(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone Drug Info [57]
(3-nitro-1H-pyrazol-1-yl)(phenyl)methanone Drug Info [57]
(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone Drug Info [57]
(4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone Drug Info [57]
(4-nitro-1H-pyrazol-1-yl)(phenyl)methanone Drug Info [57]
1,2,3,4,6-penta-O-galloyl-beta-D-glucose Drug Info [58]
1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE Drug Info [59]
1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide Drug Info [57]
2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine Drug Info [60]
2-NAPHTHALENESULFONIC ACID Drug Info [59]
2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine Drug Info [61]
3-(4-HYDROXY-PHENYL)PYRUVIC ACID Drug Info [59]
3-chlorophenyl 2-oxo-2H-chromene-3-carboxylate Drug Info [62]
4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL Drug Info [59]
4-(3,4-Diethoxy-benzylamino)-benzamidine Drug Info [63]
4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine Drug Info [63]
4-Iodobenzo[B]Thiophene-2-Carboxamidine Drug Info [59]
4-TERT-BUTYLBENZENESULFONIC ACID Drug Info [59]
4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE Drug Info [59]
5-desgalloylstachyurin Drug Info [58]
6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE Drug Info [59]
AC-(D)PHE-PRO-BOROHOMOLYS-OH Drug Info [59]
AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH Drug Info [59]
AC-(D)PHE-PRO-BOROLYS-OH Drug Info [59]
AZD-8165 Drug Info [64]
AZD0837 Drug Info [65]
Bbs-Arg-(D-Pip)-Gly-(EQKLISEEDL)-Gly-Hir Drug Info [66]
Bbs-Arg-(D-Pip)-Gly-(SPH(pY)EKVS)-Gly-Hir Drug Info [66]
Bbs-Arg-(D-Pip)-Gly-(SPHYEKVS)-Gly-Hir Drug Info [66]
Bbs-Arg-(D-Pip)-Gly-S-(GS)1-Gly-Hir Drug Info [66]
Bbs-Arg-(D-Pip)-Gly-S-(GS)11-Gly-Hir Drug Info [66]
Bbs-Arg-(D-Pip)-Gly-S-(GS)13-Gly-Hir Drug Info [66]
Bbs-Arg-(D-Pip)-Gly-S-(GS)3-Gly-Hir Drug Info [66]
Bbs-Arg-(D-Pip)-Gly-S-(GS)5-Gly-Hir Drug Info [66]
Bbs-Arg-(D-Pip)-Gly-S-(GS)7-Gly-Hir Drug Info [66]
Bbs-Arg-(D-Pip)-Gly-S-(GS)9-Gly-Hir Drug Info [66]
BCH-2763 Drug Info [67]
BCX-1470 Drug Info [68]
BENZOTHIAZOLE Drug Info [59]
Beta-(2-Naphthyl)-Alanine Drug Info [59]
Beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide Drug Info [59]
Bivalirudin Drug Info [69]
Bivalirudine Drug Info [70]
BMS-189664 Drug Info [71]
BMS-344577 Drug Info [72]
BMS-740808 Drug Info [73]
CASUARIIN Drug Info [58]
CHLORODYSINOSIN A Drug Info [74]
CJC-1004 Drug Info [75]
COCHINCHINENENE B Drug Info [76]
COCHINCHINENIN B Drug Info [76]
CRA_8696 Drug Info [59]
CVS-1123 Drug Info [77]
CVS-995 Drug Info [78]
Cyclotheonamide E Drug Info [79]
Cyclotheonamide E4 Drug Info [79]
Cyclotheonamide E5 Drug Info [79]
D-leucyl-N-(3-chlorobenzyl)-L-prolinamide Drug Info [59]
D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide Drug Info [59]
D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide Drug Info [59]
D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide Drug Info [59]
D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide Drug Info [59]
D-phenylalanyl-N-benzyl-L-prolinamide Drug Info [59]
D-Pro-Phe-Arg chloromethyl ketone Drug Info [80]
Dabigatran Drug Info [5]
Dermolastin Drug Info [81], [82], [83], [84]
Desirudine Drug Info [70]
DP-4088 Drug Info [64]
DuP 714 Drug Info [85]
DYSINOSIN A Drug Info [74]
Efegatran Drug Info [85]
EFEGATRAN SULFATE HYDRATE Drug Info [71]
Enoxaprin Drug Info [86]
Gamma-Carboxy-Glutamic Acid Drug Info [87]
GR-133686 Drug Info [88]
GS-522 Drug Info [89]
GW-473178 Drug Info [90]
H376/95 Drug Info [69]
Haempatch Drug Info [64]
Hementin Drug Info [91]
Hemi-Babim Drug Info [59]
Heparin-Cantithrombin III Drug Info [92]
Hirudin Drug Info [69], [93], [94]
Hirulog Drug Info [94]
L-370,518 Drug Info [94]
L-373890 Drug Info [95]
L-374,087 Drug Info [96]
L-375378 Drug Info [97]
LB-30870 Drug Info [71]
LB30057 Drug Info [98]
LB30812 Drug Info [99]
Lepirudin Drug Info [100]
Lepirudine Drug Info [70]
Licostinel Drug Info [101]
Lysophosphotidylserine Drug Info [87]
Macrocyclic tripeptide motif Drug Info [102]
MELAGATRAN Drug Info [103]
Melogatran Drug Info [92]
Methyl L-phenylalaninate Drug Info [59]
METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE Drug Info [59]
MPC-0920 Drug Info [104]
N4-(N,N-DIPHENYLCARBAMOYL)-AMINOGUANIDINE Drug Info [59]
Napsagatran Drug Info [105]
NU-172 Drug Info [106], [107]
Odiparcil Drug Info [108]
Org-34092 Drug Info [64]
OSCILLARIN Drug Info [74]
PEDUNCULAGIN Drug Info [58]
PPACK Drug Info [85]
RAZAXABAN Drug Info [109]
RWJ-50353 Drug Info [110]
S-18326 Drug Info [71]
S-2238 Drug Info [111]
SC-79407 Drug Info [96]
SR-80027A Drug Info [112]
SSR-182289 Drug Info [71]
Tellimagrandin II Drug Info [58]
UK-156406 Drug Info [71]
Vasoflux Drug Info [113]
VE-04051645 Drug Info [64]
Ximelagatran Drug Info [114]
Modulator Anisindione Drug Info [115]
bufrudin, Biopharm Drug Info
CVS-1578 Drug Info
EP-217609 Drug Info
EP-42675 Drug Info [116]
INOGATRAN Drug Info
Pegmusirudin Drug Info [64]
Recombinant RGD-hirudin Drug Info [117]
RWJ-671818 Drug Info [23]
Solulin Drug Info [24]
SR-123781A Drug Info [118]
SSR-128428 Drug Info
TB-101 Drug Info [64]
TB-102 Drug Info [64]
Tumor vascular thrombogen Drug Info [64]
Cofactor Vitamin K Drug Info [119]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Neuroactive ligand-receptor interaction
Complement and coagulation cascades
Regulation of actin cytoskeleton
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Blood coagulation
Pathway Interaction Database Thrombin/protease-activated receptor (PAR) pathway
Angiopoietin receptor Tie2-mediated signaling
FOXA2 and FOXA3 transcription factor networks
PAR4-mediated thrombin signaling events
Syndecan-4-mediated signaling events
PAR1-mediated thrombin signaling events
PathWhiz Pathway Vitamin K Metabolism
Coagulation
Reactome Intrinsic Pathway of Fibrin Clot Formation
Common Pathway of Fibrin Clot Formation
Gamma-carboxylation of protein precursors
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus
Removal of aminoterminal propeptides from gamma-carboxylated proteins
Cell surface interactions at the vascular wall
Peptide ligand-binding receptors
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
G alpha (q) signalling events
Thrombin signalling through proteinase activated receptors (PARs)
WikiPathways Complement and Coagulation Cascades
Regulation of Actin Cytoskeleton
IL1 and megakaryotyces in obesity
Regulation of Insulin-like Growth Factor (IGF) Transport and Uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
gamma carboxylation, hypusine formation and arylsulfatase activation
Blood Clotting Cascade
Gastrin-CREB signalling pathway via PKC and MAPK
Thrombin signalling through proteinase activated receptors (PARs)
Platelet Aggregation (Plug Formation)
GPCR ligand binding
GPCR downstream signaling
Formation of Fibrin Clot (Clotting Cascade)
Cell surface interactions at the vascular wall
Folate Metabolism
Vitamin B12 Metabolism
Selenium Micronutrient Network
References
REF 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 010909.
REF 2(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6960).
REF 3Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
REF 4(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6470).
REF 5Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
REF 6(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6380).
REF 7(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6469).
REF 8ClinicalTrials.gov (NCT01960569) Topical r-Hirudin ( Thrombexx ) Efficacy in Treatment of Haematomas. U.S. National Institutes of Health.
REF 9ClinicalTrials.gov (NCT00206089) Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events. U.S. National Institutes of Health.
REF 10(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6382).
REF 11ClinicalTrials.gov (NCT00338897) Dose Ranging Study in Elective Total Hip Replacement Surgery. U.S. National Institutes of Health.
REF 12Efegatran. Institute for drug research/IVAX. IDrugs. 2001 Jun;4(6):691-4.
REF 13Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033781)
REF 14Frontiers in Anti-Infective Drug Discovery, Atta-ur-Rahman, ??. Iqbal Choudhary. Page(57).
REF 15ClinicalTrials.gov (NCT00808964) Study of NU172 as Anticoagulation in Patients Undergoing Off-pump CABG Surgery. U.S. National Institutes of Health.
REF 16ClinicalTrials.gov (NCT00240643) Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke. U.S. National Institutes of Health.
REF 17ClinicalTrials.gov (NCT00074620) A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis. U.S. National Institutes of Health.
REF 18The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits. Thromb Res. 2010 Oct;126(4):e339-43.
REF 19ClinicalTrials.gov (NCT01150812) Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects. U.S. National Institutes of Health.
REF 20(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7727).
REF 21Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028740)
REF 22Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023539)
REF 23J Med Chem. 2010 Feb 25;53(4):1843-56.Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.
REF 24The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model. J Thromb Haemost. 2011 Jun;9(6):1174-82.
REF 25Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020651)
REF 26ClinicalTrials.gov (NCT00206063) Long Term Open Follow-up With H376/95 vs. Warfarin. U.S. National Institutes of Health.
REF 27(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6381).
REF 28(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7682).
REF 29Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018351)
REF 30Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018071)
REF 31Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005012)
REF 32Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004026)
REF 33Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015478)
REF 34Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007938)
REF 35Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019755)
REF 36Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009938)
REF 37Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014574)
REF 38Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004614)
REF 39Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015039)
REF 40Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003616)
REF 41Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023381)
REF 42Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004736)
REF 43Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010067)
REF 44Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007017)
REF 45Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010403)
REF 46Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004615)
REF 47Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001867)
REF 48Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001951)
REF 49Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003259)
REF 50Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005051)
REF 51Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009558)
REF 52Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009151)
REF 53Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009139)
REF 54Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010730)
REF 55Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001987)
REF 56Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005178)
REF 57J Med Chem. 2007 Oct 4;50(20):4928-38. Epub 2007 Sep 12.N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase.
REF 58J Nat Prod. 1998 Nov;61(11):1356-60.Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade.
REF 59The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
REF 60J Med Chem. 2001 Aug 16;44(17):2753-71.Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa.
REF 61J Med Chem. 2006 Jul 13;49(14):4116-26.Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase.
REF 62J Med Chem. 2005 Dec 1;48(24):7592-603.3,6-disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa.
REF 63Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22.Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors.
REF 64(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
REF 65Clinical pipeline report, company report or official report of AstraZeneca (2009).
REF 66Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3. Epub 2005 Oct 3.Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions.
REF 67BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb Haemost. 1998 Feb;79(2):431-8.
REF 68Recent Developments in Low Molecular Weight Complement Inhibitors. Mol Immunol. 2009 December; 47(2-3): 185-195.
REF 69New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
REF 70New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32.
REF 71Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
REF 72Bioorg Med Chem Lett. 2009 Dec 15;19(24):6882-9. Epub 2009 Oct 23.Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.
REF 73Bioorg Med Chem Lett. 2008 Jan 15;18(2):749-54. Epub 2007 Nov 17.Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.
REF 74Bioorg Med Chem Lett. 2009 Sep 15;19(18):5429-32. Epub 2009 Jul 26.From natural products to achiral drug prototypes: potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifs.
REF 75Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jun;25(5):387-408.
REF 76J Nat Prod. 2007 Oct;70(10):1570-7. Epub 2007 Sep 21.Anti-Helicobacter pylori and thrombin inhibitory components from Chinese dragon's blood, Dracaena cochinchinensis.
REF 77CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. J Cardiovasc Pharmacol. 1997 Feb;29(2):240-9.
REF 78Synthesis, structure, and structure-activity relationships of divalent thrombin inhibitors containing an alpha-keto-amide transition-state mimetic. Protein Sci. 1996 Mar;5(3):422-33.
REF 79J Nat Prod. 2002 Mar;65(3):259-61.Cyclotheonamide E4 and E5, new potent tryptase inhibitors from an Ircinia species of sponge.
REF 80J Med Chem. 2008 Jun 12;51(11):3077-80. Epub 2008 May 7.Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors.
REF 81rAAt (inhaled) Arriva/Hyland Immuno. Curr Opin Mol Ther. 2006 Feb;8(1):76-82.
REF 82Bioreactor strategies for improving production yield and functionality of a recombinant human protein in transgenic tobacco cell cultures. Biotechnol Bioeng. 2009 Feb 1;102(2):508-20.
REF 83Optimization of the bioprocessing conditions for scale-up of transient production of a heterologous protein in plants using a chemically inducible viral amplicon expression system. Biotechnol Prog. 2009 May-Jun;25(3):722-34.
REF 84Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009.
REF 85Anticoagulation: the present and future. Clin Appl Thromb Hemost. 2001 Jul;7(3):195-204.
REF 86Low molecular weight heparins and their use in obstetrics and gynecology. Obstet Gynecol Surv. 1994 Jun;49(6):424-31.
REF 87How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
REF 88Bioorg Med Chem Lett. 1998 Nov 3;8(21):2955-60.5,5-trans lactone-containing inhibitors of serine proteases: identification of a novel, acylating thrombin inhibitor.
REF 89A novel oligodeoxynucleotide inhibitor of thrombin. I. In vitro metabolic stability in plasma and serum. Pharm Res. 1995 Dec;12(12):1937-42.
REF 90Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015039)
REF 91Hementin: anticoagulant protease from the salivary gland of the leech Haementeria ghilianii. J Lab Clin Med. 1984 Jan;103(1):44-58.
REF 92Thrombin inhibitors in acute coronary artery disease. Eur Heart J. 2002 Aug;23(15):1142-4.
REF 93Probing the hirudin-thrombin interaction by incorporation of noncoded amino acids and molecular dynamics simulation. Biochemistry. 2002 Nov 19;41(46):13556-69.
REF 94Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis. Thromb Haemost. 1998 Mar;79(3):656-62.
REF 95L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor. Bioorg Med Chem Lett. 1998 Apr 7;8(7):817-22.
REF 96Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis. J Thromb Thrombolysis. 2002 Oct;14(2):113-21.
REF 97Bioorg Med Chem Lett. 2003 Jan 20;13(2):161-4.Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'.
REF 98Antithrombotic activity of LB30057, a newly synthesized direct thrombin inhibitor. Thromb Haemost. 2003 Jan;89(1):104-11.
REF 99Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. J Med Chem. 2003 Aug 14;46(17):3612-22.
REF 100Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50.
REF 101Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
REF 102Novel thrombin inhibitors that are based on a macrocyclic tripeptide motif, Bioorg. Med. Chem. Lett. 6(24):2947-2952 (1996).
REF 103Bioorg Med Chem Lett. 2006 May 15;16(10):2648-53. Epub 2006 Feb 3.Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety.
REF 104Clinical pipeline report, company report or official report of MYRIAD GENETICS, INC.
REF 105Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model. J Pharmacol Exp Ther. 1996 Apr;277(1):71-8.
REF 106Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem. 2011; 18(27): 4206-4214.
REF 107Aptamers in Bioanalysis. M. Mascini. 2009. Wiley. Page(46).
REF 108A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. J Thromb Haemost. 2006 Sep;4(9):1989-96.
REF 109Bioorg Med Chem Lett. 2010 Feb 15;20(4):1373-7. Epub 2010 Jan 11.Phenyltriazolinones as potent factor Xa inhibitors.
REF 110Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. Epub 2007 Nov 6.Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.
REF 111Screening for selective thrombin inhibitors in mushrooms. Blood Coagul Fibrinolysis. 2001 Mar;12(2):123-8.
REF 112Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. Blood. 1994 Oct 15;84(8):2571-7.
REF 113Vasoflux, a new anticoagulant with a novel mechanism of action. Circulation. 1999 Feb 9;99(5):682-9.
REF 114Ximelagatran increases membrane fluidity and changes membrane lipid composition in primary human hepatocytes. Toxicol In Vitro. 2009 Jul 16.
REF 115Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6.
REF 116EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs. J Thromb Haemost. 2014 Jan;12(1):24-33.
REF 117The NMR solution structure of recombinant RGD-hirudin. Biochem Biophys Res Commun. 2007 Aug 17;360(1):103-8. Epub 2007 Jun 13.
REF 118SR123781A, a synthetic heparin mimetic. Thromb Haemost. 2001 May;85(5):852-60.
REF 119Plasma levels of protein C and vitamin K-dependent coagulation factors in patients on long-term oral anticoagulant therapy. Tohoku J Exp Med. 1986 Aug;149(4):351-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.